744 results about "Pharmaceutical technology" patented technology

The invention provides a preparation method of medicinal liquor and application of the medicinal liquor in preparation of analgesic and anti-inflammatory products, and relates to the technical field of medicines. The preparation method comprises the following steps: (1) crushing; (2) extracting; (3) standing and separating; and (4) freezing and filtering to obtain the medicinal liquor. In the preparation process, traditional Chinese medicine components are extracted through the steps of batch crushing, mixed extraction, standing, freezing and separation of supernate and suspension in different separation modes to obtain the medicinal liquor, and the medicinal liquor can better inhibit pain caused by thermal stimulation and chemical substances and has a better analgesic effect; the traditional Chinese medicine composition can inhibit capillary permeability increase caused by acetic acid, has a better effect of inhibiting inflammation exudation, and has remarkable analgesic and anti-inflammatory effects.

The invention belongs to the technical field of medicines, and particularly relates to application of Comput-8 in preparation of a product for relieving or treating retina degeneration induced by blue light damage. It is found for the first time that Compond-8 has a protection effect on retina rod cells and cone cells induced by blue light damage, the cilia length, density and membrane disc thickness of the cone cells and the rod cells can be increased, the thickness of a retina outer nuclear layer can be increased, photoreceptor cell damage caused by blue light exposure can be remarkably improved, and the photoreceptor cell damage can be remarkably reduced. The retina degeneration caused by blue light injury can be relieved or treated, and a new thought and means are provided for treatment of the retina degeneration induced by the blue light injury.

This invention relates to the field of pharmaceutical technology, specifically to a substituted pyridotriazole compound, its preparation method, and its uses. This specification discloses a substituted pyridotriazole compound that inhibits RIPK1 and / or MLK, as well as its pharmaceutically acceptable salts, stereoisomers, solvent compounds, or prodrugs. The compound is shown in formula (I), where the definitions of each group are detailed in the specification. Furthermore, this invention also discloses pharmaceutical compositions comprising this compound and their use in the preparation of medicaments for treating RIPK1-related diseases or conditions.

The invention belongs to the technical field of biochemical pharmacy, and particularly relates to a bezoar intermediate and a preparation method of bezoar. The preparation method comprises the following steps: mixing preparation raw materials and biochemical reaction liquid to obtain a mixed raw material solution; the preparation raw materials comprise bilirubin, organic active raw materials and vitamins, the biochemical reaction liquid is sterile purified water, and the bilirubin comprises bilirubin or biliverdin; and reacting the mixed raw material solution to obtain the bezoar intermediate. The content of combined bilirubin in the bezoar intermediate prepared by the preparation method provided by the invention is 75%-85%, the content of combined biliverdin is 73%-83%, and the yield is 83%-87%. According to the method, the poisoning and destroying effects of mycotoxin on the content, the yield, the biological activity and the oxidation resistance of the bezoar intermediate are effectively eliminated. The content, the yield, the oxidation resistance and the biological activity of the bezoar intermediate are greatly improved, the performance is stable, and the quality of bezoar is ensured.

The invention discloses an application of isorhamnetin in preparation of an anti-myocardial fibrosis medicine, and belongs to the technical field of medicines. The invention proposes that the isorhamnetin can effectively reduce myocardial tissue collagen deposition for the first time, and the medical application of the isorhamnetin is expanded. The isorhamnetin is used as the anti-myocardial fibrosis medicine, can effectively relieve the increase of mRNA expression levels of alpha-SMA, COL-1, COL-3, p53, PAI-1, IL-1beta and IL-6, and has the function of retarding myocardial fibrosis. The isorhamnetin is used as the active component of the anti-myocardial fibrosis medicine, the safety is high, the side effect is small, a novel anti-myocardial fibrosis treatment strategy is provided, and the application blank of the isorhamnetin in the field is filled.

The invention provides a traditional Chinese medicine preparation for treating allergic rhinitis and a preparation method thereof, and relates to the technical field of traditional Chinese medicine pharmacy, the traditional Chinese medicine preparation is prepared from radix asteris, schizonepeta spike, cynanchum paniculatum, perillaseed, spina gleditsiae, cottonrose hibiscus leaf, magnolia flower, semen brassicae, cortex lycii radicis, dendrobe, oroxylum indicum and rhodomyrtus tomentosa; an in-vitro experiment shows that the traditional Chinese medicine preparation can remarkably inhibit the activity of hyaluronidase, also can inhibit the release of beta-HEX in an RBL-2H3 cell degranulation model, reduces the HIS level in a cell supernatant, and effectively improves the morphological abnormality caused by degranulation of RBL-2H3 cells; in-vivo experiments show that the traditional Chinese medicine preparation can significantly reduce behavioral scores of mice suffering from allergic rhinitis, inhibit expression of inflammatory factors TNF-alpha, serum Ig E and OVE-sIg E levels and HA concentration, reduce histopathologic changes caused by allergic rhinitis, effectively repair immune injuries of nasal mucosa of the mice and improve the curative effect of the mice. And a safe and effective new strategy is provided for the treatment of allergic rhinitis.

This invention belongs to the field of pharmaceutical technology, specifically relating to a quinazoline-azaindole compound, its preparation method, and its application in treating Alzheimer's disease. The quinazoline-azaindole compound of this invention regulates NF-κB by inhibiting DYRK1A. k B. A series of signaling pathways, including PI3k-Akt, achieve anti-neuroinflammatory effects; quinazoline-azaindole compounds can reduce the expression of inflammatory factor-related genes in an LPS-induced BV2 microglial inflammation model, thereby reducing the levels of inflammatory factors in the hippocampus and cortex, alleviating neuronal pathological damage caused by neuroinflammation, and improving cognitive impairment caused by neuroinflammation; in summary, quinazoline compounds inhibit DYRK1A and downregulate NF-κB signaling pathways. k It can reduce the expression and release of inflammatory factors, improve brain tissue pathology, and alleviate cognitive impairment through signaling pathways such as B, and has significant clinical application value.

The invention discloses a thiochromanone derivative containing a thiosemicarbazone structure and application of the thiochromanone derivative, relates to the technical field of medicines, and particularly relates to the technical field that the compound has better oxidation resistance and alpha-glucosidase resistance activity, the IC50 value of the compound 1-(7-chloro-4, 4-dioxothiochromanone-3-N-propyl) thiosemicarbazone to ABTS clearance activity is 2.86 [mu] g / mL, the IC50 value of the compound 1-(7-chloro-4, 4-dioxothiochromanone-3-N-propyl) thiosemicarbazone to alpha-glucosidase inhibition activity is 9.51 [mu] g / mL, and the effect is the best and is superior to that of a control agent vitamin E and acarbose. The thiochromanone derivative containing the thiosemicarbazone structure has a general formula shown in the specification,

This invention provides the application of CTH inhibitors and / or xCT inhibitors in the preparation of drugs for inhibiting mammalian embryo implantation, relating to the field of pharmaceutical technology. This invention verifies the efficacy of cystathionine-γ-lyase (CTH) inhibitors and / or solute carrier family 7 member 11 (xCT) inhibitors in inhibiting mammalian embryo implantation. The results show that xCT inhibitors and / or CTH inhibitors can significantly inhibit the proliferation of luteinized granulosa cells and progesterone secretion in mouse models. Furthermore, in vivo injection of xCT inhibitors and / or CTH inhibitors into mouse models not only significantly inhibits ovulation and the maturation rate of released oocytes, but also significantly reduces the formation of functional corpus luteum and embryo implantation. Therefore, this application provides new ideas and methods for the development of contraceptive drugs.

This application relates to the field of pharmaceutical technology, specifically to a water-for-injection generating device and a purified water distribution system. The main pipeline has an inlet end connected to the water supply pipeline of the purified water distribution system, and an outlet end connected to the return pipeline of the purified water distribution system. The branch pipeline assembly includes branch pipelines, and terminal ultrafiltration membrane modules and water-for-injection production valves, both installed on the branch pipelines. The terminal ultrafiltration membrane modules are located upstream of the water-for-injection production valve. The inlet and outlet ends of the branch pipelines are both connected to the main pipeline. The inlet end of the branch pipeline is located upstream of a first flow regulating valve, and the outlet end of the branch pipeline is located downstream of the first flow regulating valve. The purpose of this application is to address at least one technical problem mentioned in the background art by providing a water-for-injection generating device and a purified water distribution system.

This invention belongs to the field of pharmaceutical technology, specifically relating to the application of lemon balm glycosides in the preparation of drugs for the prevention or treatment of heatstroke. By constructing a mouse model of heatstroke-induced myocardial injury and observing indicators such as rectal temperature, blood routine tests, blood biochemistry, oxidative stress, and cardiac function, this invention found that lemon balm glycosides can significantly reduce the increase in rectal temperature caused by heatstroke in mice, increase the content of red blood cells and albumin in plasma, and reduce the level of oxidative stress in myocardial cells. Therefore, the application of lemon balm glycosides in the preparation of drugs for the prevention or treatment of heatstroke is proposed.

The invention discloses a device for screening strains capable of promoting synergism of specific medicinal materials and combining genetic improvement, and belongs to the technical field of biological pharmacy, the device comprises a box body, a sealing cover hinged to one side of an opening of the box body and magnetically attracted to the box body, and a shaking table structure arranged in the box body and used for shaking a culture container; the gas inlet pipe is fixedly arranged on the side, away from the opening, of the box body and communicated with the interior of the box body, and the gas injection assembly is arranged on the outer side of the box body, connected with the shaking table structure and used for intermittently introducing oxygen or nitrogen into the box body through the gas inlet pipe. According to the genetic improvement combined equipment for screening the strains capable of promoting the effect improvement of the specific medicinal materials, through the combined design of the gas injection assembly and the gas inlet pipe, the power of a shaking table structure can be transmitted to the piston assembly, so that the piston assembly sucks gas in a gas tank and injects the gas into the gas inlet pipe, intermittent introduction of the gas is realized, and the efficiency is improved. And the stability of a culture environment and the activity of the strain are further enhanced.

This invention discloses the use of ONO-2952 or a pharmaceutically acceptable salt thereof in the preparation of drugs / cosmetics for treating and / or preventing hyperpigmentation disorders, belonging to the field of pharmaceutical technology. ONO-2952 of this invention inhibits melanin synthesis induced by endogenous factors α-MSH, ACTH, and UVB radiation, thereby inhibiting melanin synthesis by suppressing the expression of key melanin synthesis proteins MITF and Tyrosinase in melanocytes. Therefore, ONO-2952 or a pharmaceutically acceptable salt thereof can be used in the preparation of drugs / cosmetics for treating and / or preventing hyperpigmentation disorders.

This invention belongs to the field of pharmaceutical technology, specifically relating to the application of oleanolic acid in promoting chondrogenic differentiation of chondrocytes. This invention discovers that oleanolic acid promotes the expression of proteoglycans and calcium deposition in ATDC5 cells undergoing chondrogenic differentiation, and also promotes the expression of ATDC5 cell chondrogenic differentiation markers. Therefore, it has the potential to be formulated into a drug that can promote chondrogenic differentiation of chondrocytes, thereby promoting cartilage repair and regeneration for the treatment of osteoarthritis and rheumatoid arthritis.

This invention relates to the field of pharmaceutical technology, and discovers that the natural products boldinine and norboldinine can be used as NTSR1 (Neurotensin receptor-1, NTSR1) receptor antagonists and their applications. The compounds are boldinine and norboldinine ((+)-Laurolitsine), which have NTSR1 receptor antagonistic activity and are NTSR1 receptor antagonists that can prevent and treat alcohol poisoning, addiction, schizophrenia, autism spectrum disorder, and mood disorders. Accordingly, this invention can provide novel NTSR1 receptor antagonist prospective compounds with clear targets for the above-mentioned related diseases.

The invention discloses a medicine manufacturing technological process, relates to the technical field of pharmacy, and solves the technical problem that long-chain unsaturated fatty acid cannot be effectively removed in an existing technical scheme. The medicine manufacturing technological process comprises badger skin and comprises the steps that 1, badger skin fat is minced and mixed with water and sodium chloride to be heated, moisture is evaporated, and a mixture is obtained; a mixture containing badger fat and fat residues is obtained; 2, carrying out solid-liquid separation on the mixture obtained in the step 1 to obtain crude badger fat and fat residues; step 3, mixing the crude badger fat obtained in the step 2 with water, heating to boiling, then cooling, and obtaining an oleic acid intermediate by utilizing an oil-water separation technology; a pure physical method of low-temperature fractional crystallization and high-speed centrifugal separation is adopted to replace a traditional chemical alkali refining method, introduction of any chemical reagent in the production process is avoided, the risk of chemical residues is fundamentally eradicated, and the pure natural property and safety of a final product are guaranteed.

The invention relates to the technical field of medicines, in particular to a composition with ingenane diterpenoid compounds as chemotherapeutic drug sensitizers and application of the composition. The chemotherapeutic drug sensitizer and the composition thereof provided by the invention can be used as the chemotherapeutic drug sensitizer, especially the sensitizer of breast cancer treatment drugs, and can be used for increasing the sensitivity of breast cancer cells to the chemotherapeutic drugs by inhibiting CHK1 (Ser345) phosphorylation so as to realize sensitization and provide a new treatment strategy for treating breast cancer.

The present invention belongs to the field of chemical and pharmaceutical technologies. Disclosed in the present invention are a benzothiophene deuterated compound and the use thereof. The benzothiophene deuterated compound as represented by formula I provided by the present invention can be used as an NLRP3 inhibitor, has high activity and excellent pharmacokinetic properties, and provides a new path for treating NLRP3-related diseases.

This invention provides a naphthopyrimidine-fused-acid sugar derivative, its synthesis method, and its application, belonging to the field of pharmaceutical technology. The naphthopyrimidine-fused-acid sugar derivative has the structures shown in formulas (I) to (IV). These compounds are obtained by one-step cyclization via a condensation reaction with 1,8-diaminonaphthalene in an organic solvent under the catalysis of a trifluoromethanesulfonate catalyst, using a propionyl-protected and p-toluenesulfonated sugar as the starting material. The preparation method is efficient and simple. The compounds of this invention exhibit good anti-proliferative activity against colon cancer tumor cells.

The utility model relates to the technical field of pharmacy, and particularly discloses a pharmaceutical powder conveying pipeline convenient to clean, which comprises a pipeline body, an auxiliary mechanism is arranged on the arc surface of the pipeline body, the auxiliary mechanism comprises a concave hole formed in the arc surface of the pipeline body, and a cover plate is arranged on the inner wall of the concave hole. A water pipe is installed on the surface of the cover plate, the arc surface of the water pipe communicates with a plurality of spray heads, the ends, away from the water pipe, of the multiple spray heads penetrate through the cover plate, two clamping holes are formed in one end of the pipeline body, and clamping rods are slidably inserted into the inner walls of the two clamping holes. By using the spray head, cleaning liquid can be sprayed into the pipeline body, so that residual medicine powder on the inner wall of the pipeline body can be removed, the cover plate can be disassembled and assembled by means of mutual clamping of the clamping hole and the clamping rod, and therefore a worker can conveniently clean the inner wall of the pipeline body after cleaning the inner wall of the pipeline body. And water stains in the pipeline body can be wiped.

The invention discloses vonoprazan fumarate, intragastric retention tablets of the vonoprazan fumarate and application of the vonoprazan fumarate to gastrointestinal tracts, and relates to the technical field of medicines.The vonoprazan fumarate is prepared through a synthesis method comprising the following steps that in the presence of an organic solvent and alkali, 5-(2-fluorophenyl) pyrrole-3-formaldehyde and pyridine-3-sulfonyl chloride are subjected to a reaction, and the vonoprazan fumarate is obtained. Hydroxypropyl-beta-cyclodextrin is added into a reaction system, and a compound WNLZ-1 is generated; reacting the compound WNLZ-1 with methylamine, and then reducing to obtain a compound WNLZ-3; the compound WNLZ-3 and fumaric acid are subjected to a salt forming reaction, and vonoprazan fumarate is obtained. According to the preparation method, hydroxypropyl-beta-cyclodextrin is introduced as a reaction accelerant in the synthesis step, the yield and purity of an intermediate are improved, meanwhile, hydroxypropyl-beta-cyclodextrin and xanthan gum are jointly used in the preparation, and the whole process optimization from raw material medicine synthesis to preparation performance is achieved.

This invention relates to the field of pharmaceutical technology. The invention provides a traditional Chinese medicine gel, comprising, by weight percentage: 0.5-5% traditional Chinese medicine exosomes, 5-15% traditional Chinese medicine extracts, 10-25% gel matrix, 1-5% transdermal penetration enhancer, 2-8% moisturizer, 0.1-0.5% preservative, 0.05-0.3% pH adjuster, and the balance deionized water. The traditional Chinese medicine gel prepared using the technical solution of this invention uses traditional Chinese medicine exosomes as the core active ingredient, combined with traditional Chinese medicine extracts, and leverages the advantages of a gel formulation to achieve highly efficient transdermal absorption of the active ingredients. It can specifically treat acne caused by internal dampness, and is highly safe, stable, and easy to use.

This invention relates to the field of pharmaceutical technology, and discloses a stress particle targeted degrader, its preparation method, and its applications. The compounds provided by this invention include ternary complexes composed of stress particle protein, a linker group, and an E3 ubiquitin ligand, or ternary complexes composed of stress particle protein, a linker group, and a ribonuclease L ligand. Compounds with different ligands exhibit good targeting and degradation effects on stress particles and can be used as stress particle targeted degraders in the preparation of antitumor drugs and anti-neurodegenerative disease drugs, showing promising application prospects in treating stress particle-induced tumor drug resistance and neurodegenerative diseases.

This invention discloses the application of ferrous ions in the preparation of products for treating bacterial infections, belonging to the field of pharmaceutical technology. Antibacterial activity tests of ferrous ions against Staphylococcus aureus showed strong bactericidal effects, with a survival rate of less than 0.001% against Staphylococcus aureus and less than 0.01% against methicillin-resistant Staphylococcus aureus (MRSA). The use of ferrous ion-containing hydrogels in the treatment of keratitis and skin wound infections significantly reduced the risk of MRSA infection in the lungs and effectively prevented the proliferation and spread of microorganisms in the body, revealing that drugs containing ferrous compounds can be used to treat Staphylococcus aureus infections, including MRSA.

This invention belongs to the field of pharmaceutical technology, specifically relating to ligand modulators targeting the estrogen-related receptor ERRγ and their uses. In a first aspect, this invention provides the use of small molecule compounds in the preparation of ligand modulators targeting the estrogen-related receptor ERRγ, said small molecule compounds being as shown in formula (I). In a second aspect, this invention also provides the use of the small molecule compounds described in the first aspect in the preparation of drugs for the prevention or treatment of ERRγ-related diseases. This invention provides a series of small molecule compounds targeting the estrogen-related receptor ERRγ as its ligand modulators, solving the problem of low drugability of ERRγ and providing more options for the development of related drugs, thus showing good prospects for development and utilization.

This invention provides a method for obtaining ingredients from Dulong Paris polyphylla (… Paris dulongensis A method for preparing parisyunnanoside G (PFE55) in H. Li & Kurita and its application in cosmetics and pharmaceuticals. This research belongs to the field of cosmetics and pharmaceutical technology. PFE55 is used at extremely low concentrations (0.1... μ At a concentration of g / mL, it exhibits activity in promoting collagen secretion in adult dermal fibroblasts (HDFa) and is non-cytotoxic at this concentration, making it suitable for the preparation of anti-aging drugs or skincare products.

This invention relates to the field of pharmaceutical technology and discloses a method for improving the clarity and color of oxybuprocaine hydrochloride solution, comprising the following steps: S110: Oxoplasmin is added to a reactor, and an organic solvent is added while stirring to control the reaction system at 0-10°C; an antioxidant is added. S120: Hydrochloric acid is slowly added in batches to the temperature-controlled reaction system. After the addition is complete, the temperature is controlled at 0-10°C for 2-4 hours, then the temperature is raised to 40-50°C for 2-4 hours, and activated carbon is added. S130: The mixture is filtered while hot, and solvent is slowly added dropwise to the filtrate until the product precipitates. After slurrying at 25-35°C for 2 hours, the mixture is filtered, and the filter cake is vacuum dried in a vacuum drying oven at 40-50°C for 12-16 hours to obtain oxybuprocaine hydrochloride. This invention provides a novel method for obtaining oxybuprocaine hydrochloride by adding antioxidants and activated carbon in the salt formation step. The clarity and color of the resulting product solution meet pharmacopoeia requirements.

The invention relates to the technical field of pharmacy, in particular to a dibenzyl butane type lignan LCA analogue as well as a preparation method and application thereof. Based on the structural characteristics of a JAK1 inhibitor, LCA is taken as a skeleton, druggability optimization and a direct drug design and structure simplification strategy based on a receptor structure are comprehensively utilized, a nitrogen-containing heterocyclic ring and a nitrogen-containing functional group are introduced into a side chain, systematic structural modification and simplification are carried out, and a series of novel LCA derivatives are designed and synthesized. The invention aims to obtain an anti-RA JAK1 inhibition candidate compound with higher activity, higher selectivity and potential.

This invention belongs to the field of pharmaceutical technology, specifically relating to biomimetic nanomedicines for treating subcutaneous drug-resistant bacterial infections, their preparation methods, and applications. In this invention, dopamine hydrochloride is added during the synthesis of a metal-organic framework to prepare a dandelion-shaped carbon nanozyme precursor. This precursor is then carbonized to obtain a carbon nanozyme with targeting, photoresponsiveness, and peroxidase activity. Finally, berberine hydrochloride is loaded onto the carbon nanozyme to obtain the biomimetic nanomedicine. The biomimetic nanomedicine provided by this invention firstly possesses good biocompatibility; secondly, it has a unique dandelion-like morphology, which is beneficial for its targeting effect; and finally, it exhibits strong photoresponsiveness in the near-infrared region, enabling synergistic and efficient bactericidal action through the mechanisms of antibacterial drugs, photothermal therapy, and chemokinetics. It has significant application value in the preparation of drugs for treating subcutaneous drug-resistant bacterial infections.

This invention belongs to the field of pharmaceutical technology, specifically relating to the application of a traditional Chinese medicine composition in the preparation of drugs for improving cognitive impairment. By weight, the traditional Chinese medicine composition comprises: 225-300 parts rhubarb, 50-75 parts pig bile powder, 90-120 parts aster, 360-480 parts scrophularia, 180-240 parts immature bitter orange peel, and 180-240 parts areca nut. This invention is the first to demonstrate that a composition of six traditional Chinese medicines, including scrophularia, rhubarb, and areca nut, significantly improves memory acquisition (induced by scopolamine), consolidation (induced by sodium nitrite), and retrieval impairments, covering the entire process of memory formation, encoding, storage, and retrieval, thus overcoming the limitations of existing drugs that only target a single memory stage.